Recent Quotes

My Watchlist

Indicators

Entheon Biomedical Corp (OP: ENTBF )

0.0862 +0.0162 (+23.14%)

Streaming Delayed Price Updated: 2:36 PM EST, Nov 4, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	800
Open	0.0600
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	0.0700
Today's Range	0.0600 - 0.0862
52wk Range	0.0043 - 0.2000
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them

August 30, 2022

The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business...

Via Benzinga

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Poised to Accelerate Its CYB004 Clinical Development Program

August 03, 2022

Via Investor Brand Network

Performance

YTD	+1064.86%	+1064.86%
1 Month	+53.93%	+53.93%
3 Month	+108.21%	+108.21%
6 Month	-35.29%	-35.29%
1 Year	+788.66%	+788.66%

More News

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Acquires DMT Study Expected to Accelerate Clinical Development Path of CYB004

July 11, 2022

Via Investor Brand Network

Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill

June 15, 2022

Via Benzinga

Largest Phase-1 DMT Study In The Netherlands, A Collaboration Between Entheon & Cybin

June 07, 2022

Via Benzinga

Ehave Partners With Halugen Life Sciences To Create A Ketamine Precision Medicine Platform For Clinical Research

June 01, 2022

Via Benzinga

Entheon Biomedical Announces Non-Brokered Private Placement Financing

April 05, 2022

Via Benzinga

Benzinga's Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th

February 09, 2022

Via Benzinga

Psyched: Psychedelics ETF Launches On NYSE, Psilocybin Trial Approved For Depression, DMT Study Begins

February 07, 2022

Via Benzinga

Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient

February 03, 2022

Via Benzinga

Entheon Biomedical Reports Launching Multiple Studies to Advance Psychedelic-Based Mental Health Treatments

December 13, 2021

Via Benzinga

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) Featured in Virtual Coverage of Benzinga’s Small Cap Conference

December 07, 2021

Via Investor Brand Network

Compass Pathways 2.0: A New Rally In Psychedelic Stocks?

November 04, 2021

Via Talk Markets

Entheon Biomedical Provides Corporate Update on Studies and Clinical Trials

October 27, 2021

Via Newsfile

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation

October 18, 2021

Via Benzinga

Entheon Biomedical Acquires Lobo Genetics, Inc. in Bid to Strengthen Screening and Treatment Evaluation Tech for Psychedelics

October 06, 2021

Via Benzinga

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are

October 13, 2021

Via Benzinga

Clinical Director of Imperial College's Center for Psychedelic Research Joins Entheon Advisory Board

August 25, 2021

Via Newsfile

Entheon Biomedical Corp. Announces DTC Eligibility

August 24, 2021

Via Newsfile

CORRECTION FROM SOURCE: BTV Examines the Rapidly Expanding Psychedelics Market

August 17, 2021

Via Newsfile

BTV Examines the Rapidly Expanding Psychedelics Market

August 17, 2021

Via Newsfile

Entheon Biomedical Announces Sponsorship of a Clinical Study to Assess the Electroneurophysiologic Effects of Ketamine

August 12, 2021

Via Newsfile

Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected

August 02, 2021

Via Benzinga

Entheon Biomedical Corp. Strengthens Its Psychedelic-Assisted Protocols Through Acquisition Of Lobo Genetics

July 30, 2021

Via Benzinga

Entheon Biomedical Corp. Acquires Lobo Genetics Inc.

July 30, 2021

Via Newsfile

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.